Prospective Evaluation of HIV Testing Technologies in a Clinical Setting: Protocol for Project DETECT

Joanne D Stekler, Lauren R Violette, Hollie A Clark, Sarah J McDougal, Lisa A Niemann, David A Katz, Pollyanna R Chavez, Laura G Wesolowski, Steven F Ethridge, Vanessa M McMahan, Andy Cornelius-Hudson, Kevin P Delaney, Joanne D Stekler, Lauren R Violette, Hollie A Clark, Sarah J McDougal, Lisa A Niemann, David A Katz, Pollyanna R Chavez, Laura G Wesolowski, Steven F Ethridge, Vanessa M McMahan, Andy Cornelius-Hudson, Kevin P Delaney

Abstract

Background: HIV testing guidelines provided by the Centers for Disease Control and Prevention (CDC) are continually changing to reflect advancements in new testing technology. Evaluation of existing and new point-of-care (POC) HIV tests is crucial to inform testing guidelines and provide information to clinicians and other HIV test providers. Characterizing the performance of POC HIV tests using unprocessed specimens can provide estimates for the window period of detection, or the time from HIV acquisition to test positivity, which allows clinicians and other HIV providers to select the appropriate POC HIV tests for persons who may be recently infected with HIV.

Objective: This paper describes the protocols and procedures used to evaluate the performance of the newest POC tests and determine their sensitivity during early HIV infection.

Methods: Project DETECT is a CDC-funded study that is evaluating POC HIV test performance. Part 1 is a cross-sectional, retrospective study comparing behavioral characteristics and HIV prevalence of the overall population of the Public Health-Seattle & King County (PHSKC) Sexually Transmitted Disease (STD) Clinic to Project DETECT participants enrolled in part 2. Part 2 is a cross-sectional, prospective study evaluating POC HIV tests in real time using unprocessed whole blood and oral fluid specimens. A POC nucleic acid test (NAT) was added to the panel of HIV tests in June 2018. Part 3 is a longitudinal, prospective study evaluating seroconversion sensitivity of POC HIV tests through serial follow-up testing. For comparison, HIV-1 RNA and HIV-1/HIV-2 antigen/antibody tests are also performed for participants enrolled in part 2 or 3. A behavioral survey that collects information about demographics, history of HIV testing, STD history, symptoms of acute HIV infection, substance use, sexual behaviors in the aggregate and with recent partners, and use of pre-exposure prophylaxis and antiretroviral therapy is completed at each part 2 or 3 visit.

Results: Between September 2015 and March 2019, there were 14,990 Project DETECT-eligible visits (part 1) to the PHSKC STD Clinic resulting in 1819 part 2 Project DETECT study visits. The longitudinal study within Project DETECT (part 3) enrolled 27 participants with discordant POC test results from their part 2 visit, and 10 (37%) were followed until they had fully seroconverted with concordant positive POC test results. Behavioral survey data and HIV test results, sensitivity, and specificity will be presented elsewhere.

Conclusions: Studies such as Project DETECT are critical for evaluating POC HIV test devices as well as describing characteristics of persons at risk for HIV acquisition in the United States. HIV tests in development, including POC NATs, will provide new opportunities for HIV testing programs.

International registered report identifier (irrid): RR1-10.2196/16332.

Keywords: HIV testing; acute HIV infection; nucleic acid tests; point-of-care tests.

Conflict of interest statement

Conflicts of Interest: None declared.

©Joanne D Stekler, Lauren R Violette, Hollie A Clark, Sarah J McDougal, Lisa A Niemann, David A Katz, Pollyanna R Chavez, Laura G Wesolowski, Steven F Ethridge, Vanessa M McMahan, Andy Cornelius-Hudson, Kevin P Delaney. Originally published in JMIR Research Protocols (http://www.researchprotocols.org), 27.01.2020.

Figures

Figure 1
Figure 1
Project DETECT study design.
Figure 2
Figure 2
Project DETECT part 3 procedures. Ag/Ab: antigen/antibody; NAT: nucleic acid test; DBS: dries blood spot.

References

    1. Delaney KP, Wesolowski LG, Owen SM. The evolution of HIV testing continues. Sex Transm Dis. 2017 Dec;44(12):747–749. doi: 10.1097/OLQ.0000000000000736.
    1. Pilcher CD, Tien HC, Eron JJ, Vernazza PL, Leu S, Stewart PW, Goh L, Cohen MS, Quest Study. Duke-UNC-Emory Acute HIV Consortium Brief but efficient: acute HIV infection and the sexual transmission of HIV. J Infect Dis. 2004 May 15;189(10):1785–1792. doi: 10.1086/386333.
    1. Centers for Disease Control and Prevention Detection of acute HIV infection in two evaluations of a new HIV diagnostic testing algorithm—United States, 2011-2013. MMWR Morb Mortal Wkly Rep. 2013 Jun 21;62(24):489–494.
    1. White DAE, Giordano TP, Pasalar S, Jacobson KR, Glick NR, Sha BE, Mammen PE, Hunt BR, Todorovic T, Moreno-Walton L, Adomolga V, Feaster DJ, Branson BM. Acute HIV discovered during routine HIV screening with HIV antigen-antibody combination tests in 9 US emergency departments. Ann Emerg Med. 2018 Jul;72(1):29–40. doi: 10.1016/j.annemergmed.2017.11.027.
    1. Peters PJ, Westheimer E, Cohen S, Hightow-Weidman LB, Moss N, Tsoi B, Hall L, Fann C, Daskalakis DC, Beagle S, Patel P, Radix A, Foust E, Kohn RP, Marmorino J, Pandori M, Fu J, Samandari T, Gay CL. Screening yield of HIV antigen/antibody combination and pooled HIV RNA testing for acute HIV infection in a high-prevalence population. JAMA. 2016 Feb 16;315(7):682–690. doi: 10.1001/jama.2016.0286.
    1. Centers for Disease Control and Prevention. 2014. Jun 27, [2019-05-31]. Laboratory testing for the diagnosis of HIV infection: updated recommendations .
    1. Delaney KP, Hanson DL, Masciotra S, Ethridge SF, Wesolowski L, Owen SM. Time until emergence of HIV test reactivity following infection with HIV-1: implications for interpreting test results and retesting after exposure. Clin Infect Dis. 2017 Jan 01;64(1):53–59. doi: 10.1093/cid/ciw666.
    1. Fiebig EW, Wright DJ, Rawal BD, Garrett PE, Schumacher RT, Peddada L, Heldebrant C, Smith R, Conrad A, Kleinman SH, Busch MP. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS. 2003 Sep 05;17(13):1871–1879. doi: 10.1097/01.aids.0000076308.76477.b8.
    1. Centers for Disease Control and Prevention. 2019. Apr 22, [2019-05-31]. HIV testing in clinical settings .
    1. Stekler JD, Ure G, O'Neal JD, Lane A, Swanson F, Maenza J, Stevens C, Coombs RW, Dragavon J, Swenson PD, Golden MR. Performance of Determine Combo and other point-of-care HIV tests among Seattle MSM. J Clin Virol. 2016 Mar;76:8–13. doi: 10.1016/j.jcv.2015.12.011.
    1. Stekler JD, Swenson PD, Coombs RW, Dragavon J, Thomas KK, Brennan CA, Devare SG, Wood RW, Golden MR. HIV testing in a high-incidence population: is antibody testing alone good enough? Clin Infect Dis. 2009 Aug 01;49(3):444–453. doi: 10.1086/600043.
    1. Centers for Disease Control and Prevention. 2018. Jun, [2019-05-31]. Advantages and disadvantages of FDA-approved HIV assays used for screening .
    1. Chavez P, Bradley H, Wesolowski L, Violette L, Katz D, Niemann L, McMahan V, McDougal J, Cornelius-Hudson A, Ure G, Ethridge S, Stekler J, Delaney K. Performance evaluation of four point-of-care HIV tests using unprocessed specimens: baseline data from Project DETECT. HIV Diagnostics Conference; 2019; Atlanta. 2019.
    1. Ritchie AV, Ushiro-Lumb I, Edemaga D, Joshi HA, De Ruiter A, Szumilin E, Jendrulek I, McGuire M, Goel N, Sharma PI, Allain J, Lee HH. SAMBA HIV semiquantitative test, a new point-of-care viral-load-monitoring assay for resource-limited settings. J Clin Microbiol. 2014 Sep;52(9):3377–3383. doi: 10.1128/JCM.00593-14.
    1. Ritchie AV, Goel N, Sembongi H, Lehga J, Farleigh LE, Edemaga D, Wisniewski CA, Lee HH. Performance evaluation of the point-of-care SAMBA I and II HIV-1 Qual whole blood tests. J Virol Meth. 2016 Nov;237:143–149. doi: 10.1016/j.jviromet.2016.08.017.
    1. Schacker T, Collier AC, Hughes J, Shea T, Corey L. Clinical and epidemiologic features of primary HIV infection. Ann Intern Med. 1996 Aug 15;125(4):257–264. doi: 10.7326/0003-4819-125-4-199608150-00001.
    1. Delaney K, Violette L, Niemann L, Ure G, Cornelius-Hudson A, Ethridge S, Chavez P, McMahan V, Clark H, Katz D, Stekler J. Participation in group sex and associated STD risk among MSM presenting at the Seattle/King County STD clinic. STD Prevention Conference; 2018; Washington. 2018.
    1. Tate CC, Ledbetter JN, Youssef CP. A two-question method for assessing gender categories in the social and medical sciences. J Sex Res. 2013;50(8):767–776. doi: 10.1080/00224499.2012.690110.
    1. Tordoff DM, Morgan J, Dombrowski JC, Golden MR, Barbee LA. Increased ascertainment of transgender and nonbinary patients using a 2-step versus 1-step gender identity intake question in an STD clinic setting. Sex Transm Dis. 2019 Apr;46(4):254–259. doi: 10.1097/OLQ.0000000000000952.
    1. HIV/AIDS Epidemiology Unit, Infectious Disease Assessment Unit, Washington State Department of Health. 2019. [2019-05-31]. HIV/AIDS epidemiology report 2018, volume 87 .
    1. Chavez P, Wesolowski L, Violette L, Niemann L, McMahan V, Cornelius-Hudson A, Katz D, Ethridge S, Stekler J, Delaney K. Specificity of 4 point-of-care rapid HIV tests in a setting with high PrEP use. Conference on Retroviruses and Opportunistic Infections (CROI); 2019; Seattle. 2019.
    1. Delaney K, Violette L, Ure G, Cornelius-Hudson A, Niemann L, Wesolowski L, Chavez P, Ethridge S, McMahan V, Clark H, Katz D, Stekler J. Time from HIV infection to earliest detection for 4 FDA-approved point-of-care tests. Conference on Retroviruses and Opportunistic Infections (CROI); 2018; Boston. 2018.
    1. Violette L, Cornelius-Hudson A, Assennato S, Ritchie A, Goel N, Niemann L, Chavez P, Ethridge S, Katz D, McMahan V, Wesolowski L, Lee H, Delaney K, Stekler J. SAMBA: a point-of-care NAT for detection of HIV viremia. HIV Diagnostics Conference; 2019; Atlanta. 2019.
    1. Stekler JD, Violette LR, Niemann L, McMahan VM, Katz DA, Baeten JM, Grant RM, Delaney KP. Repeated false-positive HIV test results in a patient taking HIV pre-exposure prophylaxis. Open Forum Infect Dis. 2018 Sep;5(9):ofy197. doi: 10.1093/ofid/ofy197.
    1. Katz DA, Dombrowski JC, Bell TR, Kerani RP, Golden MR. HIV incidence among men who have sex with men after diagnosis with sexually transmitted infections. Sex Transm Dis. 2016 Apr;43(4):249–254. doi: 10.1097/OLQ.0000000000000423.
    1. Masciotra S, Price KA, Sprinkle P, Wesolowski L, Owen SM. Performance evaluation of the CHEMBIO DPP (dual path platform) HIV-1/2 assay in early and established infections. J Clin Virol. 2015 Sep;70:97–100. doi: 10.1016/j.jcv.2015.07.005.
    1. Masciotra S, Luo W, Westheimer E, Cohen SE, Gay CL, Hall L, Pan Y, Peters PJ, Owen SM. Performance evaluation of the FDA-approved Determine HIV-1/2 Ag/Ab Combo assay using plasma and whole blood specimens. J Clin Virol. 2017 Jun;91:95–100. doi: 10.1016/j.jcv.2017.03.019.
    1. Adams S, Luo W, Wesolowski L, Cohen SE, Peters PJ, Owen SM, Masciotra S. Performance evaluation of the point-of-care INSTI HIV-1/2 antibody test in early and established HIV infections. J Clin Virol. 2017 Jun;91:90–94. doi: 10.1016/j.jcv.2017.03.012.
    1. Masciotra S, Luo W, Youngpairoj AS, Kennedy MS, Wells S, Ambrose K, Sprinkle P, Owen SM. Performance of the Alere Determine HIV-1/2 Ag/Ab Combo Rapid Test with specimens from HIV-1 seroconverters from the US and HIV-2 infected individuals from Ivory Coast. J Clin Virol. 2013 Dec;58 Suppl 1:e54–e58. doi: 10.1016/j.jcv.2013.07.002.
    1. Wesolowski LG, Delaney KP, Meyer WA, Blatt AJ, Bennett B, Chavez P, Granade TC, Owen M. Use of rapid HIV assays as supplemental tests in specimens with repeatedly reactive screening immunoassay results not confirmed by HIV-1 Western blot. J Clin Virol. 2013 Sep;58(1):240–244. doi: 10.1016/j.jcv.2013.06.019.
    1. Hood JE, Buskin SE, Dombrowski JC, Kern DA, Barash EA, Katzi DA, Golden MR. Dramatic increase in preexposure prophylaxis use among MSM in Washington state. AIDS. 2016 Jan 28;30(3):515–519. doi: 10.1097/QAD.0000000000000937.
    1. Rao DW, Carr J, Naismith K, Hood JE, Hughes JP, Morris M, Goodreau SM, Rosenberg ES, Golden MR. Monitoring HIV preexposure prophylaxis use among men who have sex with men in Washington State: findings from an internet-based survey. Sex Transm Dis. 2019 Apr;46(4):221–228. doi: 10.1097/OLQ.0000000000000965.
    1. Katz DA, Dombrowski JC, Barry M, Spellman D, Bell TR, Golden MR. STD partner services to monitor and promote HIV pre-exposure prophylaxis use among men who have sex with men. J Acquir Immune Defic Syndr. 2019 Apr 15;80(5):533–541. doi: 10.1097/QAI.0000000000001952.
    1. US Food and Drug Administration Reclassification of HIV point-of-care laboratory-based serological and NAT diagnostic devices from Class III (PMA) to Class II 510(k) Issue Summary. Blood Products Advisory Committee Meeting; 2018; Silver Spring. 2018.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj